Gujarat Kidney & Super Speciality Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Gujarat Kidney & Super Speciality Ltd trades at ₹128, in a confirmed uptrend and 22 weeks into that stage. That is +9.6% against its own 200-day average. It sits at 66% of a 52-week range of ₹99 to ₹143. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).

Today the stock is in a confirmed uptrend — week 22 of stage 2, confirmed. At ₹128 it trades +9.6% versus its 200-day average and sits at 66% of its 52-week range (₹99–₹143).

Against the market, two honest reads. Cumulative: over the last 6 months the stock moved +25% while the NIFTY 500 moved −3% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 66th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Gujarat Kidney & Super Speciality Ltd trades at 65.2× P/E, mid-range by its own standards (66th percentile). Its long-run median P/E is 63.2×, measured across 0.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 65.2× is mid-range by its own standards (66th percentile), against a long-run median of 63.2× measured over 0.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Gujarat Kidney & Super Speciality Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

43.3/100 — rank 7 of 7 in Hospitals/Medical Services · 43% evidence confidence · provisional, ranked below fully-evidenced peers

Gujarat Kidney & Super Speciality Ltd scores 43.3 out of 100 against the 7 companies it is compared with in Hospitals/Medical Services, ranking 7. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 11.4 + 12.4 + 9.5 + 10 = 43.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Gujarat Kidney & Super Speciality Ltd reported ₹30.6 Cr of revenue in the Mar 26 quarter, +212.7% year on year. That is the 3rd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹82.0 Cr. The last four reported quarters add to ₹82.0 Cr.

Gujarat Kidney & Super Speciality Ltd reported ₹30.6 Cr of revenue in the Mar 26 quarter, +212.7% year on year. That is the 3rd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹82.0 Cr. The last four reported quarters add to ₹82.0 Cr.

FY26 revenue came in at ₹82.0 Cr (+105.0% on the year). The latest quarter (Mar 26) printed ₹30.6 Cr, +212.7% year on year — the 3rd consecutive quarter of year-over-year growth.

→ Revenue grew — did margins hold as it scaled? Next: 20.6% this quarter (−6.1 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Gujarat Kidney & Super Speciality Ltd's operating margin is 20.6% in the Mar 26 quarter, −6.1 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 33.0% to 41.0%. The current quarter is running below every full year in that window.

Gujarat Kidney & Super Speciality Ltd's operating margin is 20.6% in the Mar 26 quarter, −6.1 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 33.0% to 41.0%. The current quarter is running below every full year in that window.

The latest quarter's operating margin is 20.6%, −6.1 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged 33.0%–41.0%.

🚨 Why the margin moved: operating margin went −6.1 pp year on year while gross margin went +5.0 pp — the loss came mostly from the gross line: input costs and pricing.

→ Margins slipped — did that reach the bottom line? Next: profit +259.7% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Gujarat Kidney & Super Speciality Ltd earned ₹4.8 Cr of net profit in the Mar 26 quarter, +259.7% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹17.0 Cr. That is 15.8% of the quarter's revenue. The same quarter a year earlier earned ₹1.3 Cr.

Gujarat Kidney & Super Speciality Ltd earned ₹4.8 Cr of net profit in the Mar 26 quarter, +259.7% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹17.0 Cr. That is 15.8% of the quarter's revenue. The same quarter a year earlier earned ₹1.3 Cr.

Mar 26 profit was ₹4.8 Cr, +259.7% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹17.0 Cr (+70.0%).

Why profit moved: revenue contributed +212.7% and the margin −6.1 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +101.1% vs revenue +115.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit rose — but did the cash follow? Next: 38% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 38% of Gujarat Kidney & Super Speciality Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−4.0 Cr of operating cash against ₹17.0 Cr of profit. After ₹103 Cr of capital spending, ₹−107 Cr was left as free cash.

FY26: operating cash of ₹−4.0 Cr against reported profit of ₹17.0 Cr, leaving free cash of ₹−107 Cr after ₹103 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 38% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at 38%: the cash cycle tightened 405 days between FY24 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: the bigger cash user is investment — capital spending ran 17.1× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹137 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Gujarat Kidney & Super Speciality Ltd's cash conversion cycle runs −84 days in FY26, down from 321 days in FY24. Capital spending ran ₹137 Cr over the last 3 years. At FY26 sales of ₹82.0 Cr each day of that cycle holds about ₹0.2 Cr, so roughly ₹−19.0 Cr sits inside the business at any moment.

FY26: debtors at 172 days, inventory at 82 days — roughly 2.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −84 days, tighter than FY24's 321.

The full loop: cash goes out to suppliers and production on day 0; stock waits 82 days to sell; customers pay about 172 days after that; and suppliers themselves are paid at 339 days — netting out to the −84-day cycle.

In money terms: at FY26 sales of ₹82.0 Cr, each day of the cycle holds about ₹0.2 Cr — so the −84-day loop keeps roughly ₹−19.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹137 Cr over the last 3 fiscal years against ₹8.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 14% and the ROIC − WACC spread is −5.5 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Gujarat Kidney & Super Speciality Ltd earns a ROCE of 14% in FY26. Return on invested capital clears the cost of that capital by −5.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 20.7% net margin on 0.28× asset turns.

FY26 ROCE is 14%.

🚨 Why the return is what it is — the wiring (FY26): 20.7% net margin × 0.28× asset turns × 1.18× balance-sheet leverage ≈ 6.8% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 6.5% − 12.0% = a −5.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.11.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Gujarat Kidney & Super Speciality Ltd carries total debt of ₹29.0 Cr against shareholder equity of ₹255 Cr as of Mar 26, a debt-to-equity of 0.11 — effectively unlevered. On the annual view that ratio went from 0.30 in FY25 to 0.11 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹29.0 Cr against shareholder equity of ₹255 Cr — a debt-to-equity of 0.11. On the annual view, debt-to-equity went from 0.30 (FY25) to 0.11 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Gujarat Kidney & Super Speciality Ltd moved a full percentage point over the last two years — the register is quiet. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — .

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Gujarat Kidney & Super Speciality Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions